Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01168596 · ClinicalTrials.gov registry record · Phase 4

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease

A Phase 4 study of Parkinson's Disease, sponsored by University of Florida.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
3
Study locations

NCT01168596: Completed Phase 4 study of Parkinson's Disease, sponsored by University of Florida.

NCT01168596 is a Phase 4 study of Parkinson's Disease that has completed, run by University of Florida. The registered enrollment target is 30 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01168596, a Phase 4 study of Parkinson's Disease, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

The purpose of the research study is to determine if rasagiline is an effective treatment for fatigue in patients with Parkinson's disease (PD).

Primary Outcome

The MFIS rates how much of a problem fatigue has caused the subjects during the past month, including the day of testing. It consists of 21 questions of fatigue on quality of life. Each subject is asked to circle the appropriate response for each item: 0=never, 1=rarely, 2=sometimes, 3=often, 4=always, 5=almost always. The minimum score is 0 and the maximum is 105. The higher the score, the more fatigue the subject.

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG Placebo
  • DRUG Rasagiline

Study Locations (3)

Colorado

  • University of Colorado Anschutz outpatient Pavilion - Aurora

Florida

  • Shands and University of Florida Medical Plaza - Gainesville

Ohio

  • Cleveland Clinic Center for Neurological Restoration - Cleveland

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2009-12
Est. Completion 2012-05
Phase Phase 4
University of Florida

1,106 total trials

What the finished NCT01168596 record still lists

NCT01168596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01168596 reports a single indexed study location in Colorado, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT01168596 about?

NCT01168596 is a clinical study titled "Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease". The purpose of the research study is to determine if rasagiline is an effective treatment for fatigue in patients with Parkinson's disease (PD).

What is the current status of trial NCT01168596?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2009-12. Estimated completion is 2012-05.

What conditions does trial NCT01168596 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT01168596?

The interventions under investigation include: Placebo (DRUG), Rasagiline (DRUG).

Who is sponsoring clinical trial NCT01168596?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01168596 being conducted?

This trial has 3 study locations across Colorado, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01168596's enrollment target sits among peer trials

30 108th of 158 higher than 47 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01168596, the US trial registry maintained by the National Library of Medicine. NCT01168596 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.